Skip to main content
CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
57.33
-2.67 (-4.45%)
At close: Mar 5, 2026, 4:00 PM EST
55.25
-2.08 (-3.63%)
Pre-market: Mar 6, 2026, 9:10 AM EST

CRISPR Therapeutics AG Revenue by Segment
Period Ending Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019
Collaboration
- - - - 405.00M - - - 370.01M - 170.10M 100.26M 436.00K 12.78M 13.01M 913.06M
Collaboration Growth
- - - - 92,789.91% - - - 2,795.65% - 1,207.15% -89.02% -99.95% -98.58% -98.56% 155,181.80%
Grant
3.51M 3.34M 3.05M 2.68M 2.31M 2.83M 2.99M 3.02M - - - - - - - - - - - - - - -
Grant Growth
51.69% 17.96% 2.04% -11.51% -23.22% 22.63% 58.82% 100.60% - - - - - - - - - - - - - - -

Operating Expense Breakdown
Period Ending Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019
Research and Development
284.81M 283.44M 306.69M 316.96M 320.65M 333.64M 342.18M 363.57M
Research and Development Growth
-11.18% -15.05% -10.37% -12.82% -17.22% -15.69% -18.85% -17.99%
Collaboration
213.48M 170.19M 124.23M 131.21M 120.67M 130.25M 142.52M 135.02M - - - - - - - - - -
Collaboration Growth
76.92% 30.67% -12.83% -2.82% -7.36% 11.26% 7.55% 10.86% - - - - - - - - - -
General and Administrative
73.54M 73.27M 73.76M 74.32M 72.98M 71.33M 72.20M 71.76M
General and Administrative Growth
0.77% 2.71% 2.15% 3.57% -4.18% -11.77% -19.38% -25.88%
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.